The Current Status of Adjuvant Chemotherapy for Colorectal Cancer in Japan: A Paradigm Shift from Oral Fluoropyridine Single Therapy to the Oxaliplatin Regimen

被引：0

作者：

Teranishi, Nobuhisa ^{[1
]}

Uetake, Hiroyuki ^{[1
]}

机构：

[1] Natl Hosp Org NHO, Disaster Med Ctr, Dept Clin Res, 3256 Midori Cho, Tachikawa 1900014, Japan

来源：

CANCERS | 2025年 / 17卷 / 03期

关键词：

colorectal cancer; adjuvant therapy in Japan; L-OHP; 5-FU + leucovorin; ACHIEVE trial; III COLON-CANCER; STAGE-II; SURVIVAL; FLUOROURACIL; LEUCOVORIN; TRIAL; S-1;

D O I：

10.3390/cancers17030518

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The effectiveness of oxaliplatin (L-OHP) has been reported overseas; however, in Japan, the prognosis of colorectal cancer (CRC) patients is reported to be good, and there has been a long debate about the applicability of L-OHP combination therapy in Japan. In recent years, the results of the ACHIEVE trial have become clear, and the standard consensus in Japan establishes L-OHP combination therapy for a duration of 3 months as the adjuvant treatment for CRC.

引用

页数：5

共 32 条

[21] Current Status of Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy in Patients With Peritoneal Carcinomatosis From Colorectal Cancer [J].

Weber, Thomas ;

Roitman, Mark ;

Link, Karl H. .

CLINICAL COLORECTAL CANCER, 2012, 11 (03) :167-176

[22] KRAS mutational status affects oxaliplatin-based chemotherapy independently from basal mRNA ERCC-1 expression in metastatic colorectal cancer patients [J].

Basso, M. ;

Strippoli, A. ;

Orlandi, A. ;

Martini, M. ;

Calegari, M. A. ;

Schinzari, G. ;

Di Salvatore, M. ;

Cenci, T. ;

Cassano, A. ;

Larocca, L. M. ;

Barone, C. .

BRITISH JOURNAL OF CANCER, 2013, 108 (01) :115-120

[23] Using oral tegafur/uracil (UFT) plus leucovorin as adjuvant chemotherapy in stage II colorectal cancer: a propensity score matching study from Taiwan [J].

Yu, Yen-Lin ;

Tseng, Wen-Ko ;

Liao, Chun-Kai ;

Yeh, Chien-Yuh ;

Chen, Hong-Hwa ;

Liu, Yu-Hsuan ;

Liaw, Yu-Wei ;

Fan, Chung-Wei .

BMC CANCER, 2023, 23 (01)

[24] Hepatic Arterial Infusion Chemotherapy Using Fluorouracil Followed by Systemic Therapy Using Oxaliplatin Plus Fluorouracil and Leucovorin for Patients with Unresectable Liver Metastases from Colorectal Cancer [J].

Hiroshi Seki ;

Toshirou Ozaki ;

Makoto Shiina .

CardioVascular and Interventional Radiology, 2009, 32 :679-686

[25] Hepatic Arterial Infusion Chemotherapy Using Fluorouracil Followed by Systemic Therapy Using Oxaliplatin Plus Fluorouracil and Leucovorin for Patients with Unresectable Liver Metastases from Colorectal Cancer [J].

Seki, Hiroshi ;

Ozaki, Toshirou ;

Shiina, Makoto .

CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY, 2009, 32 (04) :679-686

[26] Efficacy of Adjuvant Combination Therapy With Trastuzumab and Chemotherapy in HER2-positive Early Breast Cancer: A Single Institutional Cohort Study from Clinical Practice [J].

Okamoto, Masahiro ;

Tajiri, Wakako ;

Ueo, Hiroki ;

Masuda, Takanobu ;

Ijichi, Hideki ;

Koga, Chinami ;

Nakamura, Yoshiaki ;

Taguchi, Kenichi ;

Ohno, Shinji ;

Tokunaga, Eriko .

ANTICANCER RESEARCH, 2020, 40 (06) :3315-3323

[27] The IDEA (International Duration Evaluation of Adjuvant Chemotherapy) Collaboration: Prospective Combined Analysis of Phase III Trials Investigating Duration of Adjuvant Therapy with the FOLFOX (FOLFOX4 or Modified FOLFOX6) or XELOX (3 versus 6 months) Regimen for Patients with Stage III Colon Cancer: Trial Design and Current Status [J].

Andre, Thierry ;

Iveson, Timothy ;

Labianca, Roberto ;

Meyerhardt, Jeffrey A. ;

Souglakos, Ioannis ;

Yoshino, Takayuki ;

Paul, James ;

Sobrero, Alberto ;

Taieb, Julien ;

Shields, Anthony F. ;

Ohtsu, Atsushi ;

Grothey, Axel ;

Sargent, Daniel J. .

CURRENT COLORECTAL CANCER REPORTS, 2013, 9 (03) :261-269

[28] Impact of primary tumour location and RAS/BRAF mutational status in metastatic colorectal cancer treated with first-line regimens containing oxaliplatin and bevacizumab: Prognostic factors from the AIO KRK0207 first-line and maintenance therapy trial [J].

Hegewisch-Becker, Susanna ;

Noepel-Duennebacke, Stefanie ;

Hinke, Axel ;

Graeven, Ullrich ;

Reinacher-Schick, Anke ;

Hertel, Jan ;

Lerchenmueller, Christian A. ;

Killing, Birgitta ;

Depenbusch, Reinhard ;

Al-Batran, Salah-Eddin ;

Lange, Thoralf ;

Dietrich, Georg ;

Tannapfel, Andrea ;

Arnold, Dirk .

EUROPEAN JOURNAL OF CANCER, 2018, 101 :105-113

[29] Analysis of PTEN, BRAF and PI3K status for determination of benefit from cetuximab therapy in metastatic colorectal cancer patients refractory to chemotherapy with wild-type KRAS [J].

Tural, Deniz ;

Batur, Sebnem ;

Erdamar, Sibel ;

Akar, Emre ;

Kepil, Nuray ;

Mandel, Nil Molinas ;

Serdengecti, Suheyla .

TUMOR BIOLOGY, 2014, 35 (02) :1041-1049

[30] Study protocol of a single-arm phase 2 study evaluating the preventive effect of topical hydrocortisone for capecitabine-induced hand-foot syndrome in colorectal cancer patients receiving adjuvant chemotherapy with capecitabine plus oxaliplatin (T-CRACC study) [J].

Iimura, Yohei ;

Furukawa, Naoki ;

Ishibashi, Masaaki ;

Ahiko, Yuka ;

Tanabe, Taro ;

Aikou, Susumu ;

Shida, Dai ;

Nojima, Masanori ;

Kuroda, Seiichiro ;

Boku, Narikazu .

BMC GASTROENTEROLOGY, 2022, 22 (01)

← 1 2 3 4 →